Market capitalization | $353.88m |
Enterprise Value | $102.33m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.40 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-60.81m |
Free Cash Flow (TTM) Free Cash Flow | $-46.41m |
Cash position | $254.07m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a Design Therapeutics Inc forecast:
3 Analysts have issued a Design Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.59 -0.59 |
7%
7%
|
|
EBITDA | -60 -60 |
26%
26%
|
EBIT (Operating Income) EBIT | -61 -61 |
26%
26%
|
Net Profit | -48 -48 |
34%
34%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded on December 18, 2017 by Pratik Shah and Aseem Z. Ansari and is headquartered in Carlsbad, CA.
Head office | United States |
CEO | Pratik Shah |
Employees | 124 |
Founded | 2017 |
Website | www.designtx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.